Introduction
Craniofacial bone defects can arise from trauma, infection, tumor removal, congenital malformations or degenerative skeletal diseases. Attempts to repair these defects include the use of bone autografts and allografts. However, harvesting of autografts often causes considerable donor site discomfort while yielding limited amounts of tissue, and autograft transplantation often results in resorption and autograft morbidity [Betz, 2002; Khan et al., 2005] . Allografts of demineralized bone matrix carry the risk of immunogenic rejection and disease transmission [Betz, 2002; Joyce, 2005] . The use of autologous osteogenic stem/progenitor cells could overcome many of the disadvantages of autografts and allografts [Caplan, 2005] . The calvaria, or flat bones of the skull, represent an additional source of autologous cells for tissue regeneration and repair that is easily accessible with low donor site morbidity and discomfort [Smith and Abramson, 1974; Tessier, 1982; Zins and Whitaker, 1983; Cinberg et al., 1985; Maves and Matt, 1986; Hunter et al., 1990; Frodel, 1999; Carinci et al., 2005; Smolka et al., 2005] , and may be suitable for correction of craniofacial bone defects in particular. Calvarial cells could be especially useful in pediatric patients, because the calvaria reach their adult size early in development (80% at 3-4 years, 100% at 7-8 years) creating an abundance of bone compared to other donor sites [Tessier, 1982; Maves and Matt, 1986; Hunter et al., 1990; Frodel, 1999] .
We recently showed that the stem cell marker Sca-1 is expressed in mouse calvaria throughout development [Steenhuis et al., 2008] . Primary cells within the Sca-1 + cell fraction derived from fetal day 18.5 mouse calvaria had the ability to differentiate into adipose, whereas primary cells within the Sca-1 -cell fraction derived from mouse calvaria at fetal day 18.5 had the ability to differentiate into bone and cartilage [Steenhuis et al., 2008] . These data were intriguing given that a multipotent cell line has previously been isolated from rodent calvaria. The RCJ 3.1 cell line, originally isolated from late fetal rat calvaria, differentiated in a time-dependent manner into multinucleated muscle cells (9-10 days), adipocytes (12 days), chondrocyte nodules (16 days) and mineralized bone nodules (21 days) [Grigoriadis et al., 1988] . Because cells from fetal tissues are impractical for therapeutic use in tissue regeneration, we studied the differentiation potential of postnatal calvaria-derived Sca-1 + and Sca-1 -cell fractions. In this report, we tested the ability of Sca-1 + and Sca-1 -cell fractions obtained from postnatal day 21 (PN21) mouse calvaria to differentiate into adipose and bone.
Materials and Methods

Animals
The University of Michigan committee on use and care of animals approved all experiments.
Immunohistochemistry
Vectastain Elite ABC (Vector Laboratories, Burlingame, Calif., USA) was used for immunohistochemistry. Antigenicity was recovered with DeCal Retrievel Solution (BioGenex, San Ramon, Calif., USA) and sections were incubated overnight with antimouse Sca-1 (R&D Systems, Minneapolis, Minn., USA) or antimouse osteopontin (Sigma Aldrich Corp., St. Louis, Mo., USA). Vector NovaRED substrate (Vector Laboratories) was used for visualization. Negative controls were performed by incubating the sections with buffer instead of a primary antibody (not shown).
Cell Isolation and Culture PN21 B6CBAF1/J mouse calvaria were harvested and cells were obtained by sequential digestion at 37 ° C in 2 mg/ml Collagenase A (Roche Diagnostics, Indianapolis, Ind., USA) and 0.125% trypsin (Gibco TM , Carlsbad, Calif., USA) in serum-free medium [60% DMEM low glucose (Gibco), 40% MCDB201 (Sigma), 100 U/ml penicillin and 1,000 U/ml streptomycin]. Cells from 5 digestions were pooled, passed through a 40-m cell strainer, and Sca-1 + and Sca-1 -cells were separated by immunomagnetic cell sorting (EasySep TM , Stem Cell Technologies, Vancouver, B.C., Canada). Purities of the Sca-1 + and Sca-1 -cell fractions were assessed by flow cytometry immediately after magnetic cell sorting. This was possible because the primary Sca-1 antibody provided in the Sca-1 EasySep kit is conjugated to phycoerythrin. The population of viable cells was selected by excluding very small and very large particles from the gate. Cells were plated in expansion medium, which consists of serum-free medium (see above), 2% fetal bovine serum (Hyclone, Logan, Utah, USA), 1 ! insulin transferring selenium (BD Biosciences, San Jose, Calif., USA), 1 ! linoleic acid bovine serum albumin (Sigma), 10 -9 M dexamethasone (Sigma), 10 -4 M ascorbic acid 2-phosphate (Sigma), 10 ng/ml epidermal growth factor (Sigma), 10 ng/ ml leukemia inhibitory factor (Chemicon, Temecula, Calif., USA) and 10 ng/ml platelet-derived growth factor BB (R&D Systems). Primary Sca-1 + cells were plated at 10,000/cm 2 , whereas primary Sca-1 -cells were plated at 100,000/cm 2 , because their plating efficiency was lower. Once cell densities reached 50% confluency, cells were detached with 0.25% trypsin-EDTA (Gibco) and replated at 5,000/cm 2 . Passaged Sca-1 + and Sca-1 -cells had similar plating efficiencies. For differentiation assays, Sca-1 + and Sca-1 -cells were plated at 20,000/cm 2 in expansion medium. At confluency, adipogenic differentiation was induced by replacing expansion medium with adipogenic medium [expansion medium without epidermal growth factor, leukemia inhibitory factor and platelet-derived growth factor BB, but supplemented with 100 ng/ ml insulin (Sigma)]. Alternatively, osteogenic differentiation was induced by replacing expansion medium with osteogenic medium (DMEM low glucose, 2% fetal bovine serum, 10 m M ␤ -glycerophosphate, 10 -7 M dexamethasone and 0.2 m M ascorbic acid 2-phosphate). All media were refreshed every 2-3 days.
Surgery
Transplantation was performed as was previously described for bone marrow-derived mesenchymal stem/progenitor cells (BM-MSC) [Pettway et al., 2005] . Briefly, 2-3 ! 10 6 passage 1 Sca-1 + or Sca-1 -cells were incorporated into presoaked Gelfoam absorbable gelatin sponges (Pharmacia & Upjohn, Kalamazoo, Mich., USA) by capillary action. The size of the Gelfoam implants was approximately 5 ! 5 ! 3 mm, so the approximately cell density was 25,000-40,000 cells/mm 3 . Gelfoam sponges were then transplanted subcutaneously into male nu/nu mice that were anesthetized with 90 mg/kg ketamine (Fort Dodge Animal Health, Fort Dodge, Iowa, USA) and 5 mg/kg xylazine (Lloyd Laboratories, Shenandoah, Iowa, USA). Nu/nu mice are immunodeficient and were used to prevent rejection of the implants by the animal.
Cytochemistry and Histochemistry
In vitro. For detection of adipose, cells were stained for 15 min with 3 mg/ml Oil Red O (Sigma) in 60% isopropanol. Counterstaining was performed in hematoxylin. For detection of bone, alkaline phosphatase activity was determined using an alkaline phosphatase detection assay (Chemicon).
In vivo. Implants were harvested 28 days after transplantation, and micro-radiographic analysis performed (MX20 Faxitron, Buffalo Grove, Ill., USA). Next, paraffin-embedded sections were stained with hematoxylin and eosin and the percentage bone was determined based on morphology by computer-assisted histomorphometry (Image ProPlus 5.1, Media Cybernetics, Silver Spring, Md., USA).
Quantitative Real-Time RT-PCR Total RNA was isolated from cells or implants using the RNeasy Mini Kit (Qiagen, Valencia, Calif., USA) and reverse transcription was performed on 80 ng RNA (Applied Biosystems, Foster City, Calif., USA). Quantitative real-time reverse transcription polymerase chain reaction (Q RT-PCR) was performed in triplicate on 2 l of cDNA in a reaction volume of 25 l using an ABI Prism TM 7700 sequence detector (Applied Biosystems). Expression of PPAR ␥ and collagen type II was determined using TaqMan gene expression assays (Applied Biosystems). Runx2 and osteocalcin primers and probes were purchased from Applied Biosystems. Runx2 forward primer GCCGAGCTCCGAAATGC; Runx2 reverse primer CAGATCGTTGAACCTGGCTACTT; Runx2 probe (FAM-labeled, MGB quencher) CCGCTGTTAT-GAAAAA. Osteocalcin forward primer GCGGCCCTGAGTCT-GACA; osteocalcin reverse primer GGGCTTAGGAGACA-GGGTGAT; osteocalcin probe (FAM-labeled, MGB quencher) TGGCAGGGCCTTAG. Gene expression levels were normalized to GAPDH expression levels (Applied Biosystems, VIC-labeled probe with TAMRA quencher).
Statistical Analysis
For statistical analysis of in vitro gene expression, we used a linear mixed model with cell type (Sca-1 + or Sca-1 -), medium (expansion medium or differentiation medium), and their interactions as fixed effects, and experiment (biological replicate) as a random effect. This was done to take into account the fact that there was a high degree of correlation among observations within an experiment. For statistical analysis of in vivo gene expression and histomorphometry, we used the same linear mixed model with cell type as a fixed effect and experiment as a random effect. SAS 8.2 was used to perform all statistical analyses.
Results
Sca-1 + Cells Are Located in the Calvarial Periosteum, Osteoblasts and Osteocytes, and Can Be Isolated at High Purity
Sca-1 is localized in the periosteum of PN25 mouse calvaria ( fig. 1 a) and also in osteoblasts at the bone surface and in osteocytes that are embedded within the bone matrix ( fig. 1 b) . Highly pure populations of Sca-1 + and Sca-1 -cells were obtained from PN21 mouse calvaria by immunomagnetic cell sorting ( fig. 1 c, d ). fig. 2 a, b) . Expression of the adipogenic marker PPAR ␥ was upregulated 9.2-fold in Sca-1 + cells after 21 days in adipogenic medium compared to expansion medium, but there was no upregulation of PPAR ␥ in Sca-1 -cells ( fig. 2 c) . After 21 days in adipogenic medium, PPAR ␥ expression was 6.5-fold higher in Sca-1 + cells than in Sca-1 -cells ( fig. 2 c) . The same assays were performed at passage 4 and showed that Sca-1 + cells partially retain their adipogenic differentiation potential after culture expansion ( fig. 2 d-f) . However, compared to primary Sca-1 + cells adipogenesis was diminished at passage 4 ( fig. 2 d) . Furthermore, a small portion of cells in the Sca-1 -cell fraction exhibit adipogenesis at passage 4 ( fig. 2 e) . PPAR ␥ expression was upregulated 4.4-fold in passage 4 Sca-1 + cells after 21 days in adipogenic medium compared to expansion medium ( fig. 2 f) . After 21 days in adipogenic medium, PPAR ␥ expression was also 4.4-fold higher in passage 4 Sca-1 + cells than in passage 4 Sca-1 -cells. The osteogenic marker alkaline phosphatase was detected in primary Sca-1 -cells, but not in primary Sca-1 + cells ( fig. 3 a, b) . Furthermore, expression of the osteogenic marker Runx2 was upregulated 2.9-fold in Sca-1 -cells after 14 days in osteogenic medium when compared to expansion medium ( fig. 3 c) . After 14 days in osteogenic medium, Runx2 expression was 3.7-fold higher in Sca-1 -cells than in Sca-1 + cells ( fig. 3 c) . The same assays were performed at passage 4 and showed that Sca-1 -cells retain some of their osteogenic differentiation potential after culture expansion ( fig. 3 d-f) . However, alkaline phosphatase activity is much lower in passage 4 Sca-1 -cells than in primary Sca-1 -cells ( fig. 3 e) , suggesting that many cells lose their osteogenic potential after culture expansion. In contrast, Runx2 expression in passage 4 Sca-1 -cells is still upregulated under osteogenic conditions ( fig. 3 f) . After 14 days in osteogenic medium, Runx2 expression was 2.5-fold higher in passage 4 Sca-1 -cells than in passage 4 Sca1 + cells. After 14 days in expansion medium, Runx2 expression was 1.9-fold higher in pas- However, Runx2 expression was upregulated 1.7-fold in passage 4 Sca-1 cells after 14 days in osteogenic medium when compared to expansion medium, but this was not significant (p = 0.0885). These data suggest that the osteogenic response was less robust in passage 4 Sca-1 -cells than in primary Sca-1 -cells. In summary, both primary and passage 4 Sca-1 + cells had the ability to differentiate into adipose, whereas primary and passage 4 Sca-1 -cells had the ability to differentiate into bone. No differentiation assays were performed beyond passage 4.
Sca-1 -Cells Differentiate into Bone in vivo
To study if these differences in differentiation potential could also be found in vivo, we used a well-characterized ectopic implant model [Pettway et al., 2005] . Passage 1 Sca-1 + and Sca-1 -cells were loaded onto Gelfoam sponges and transplanted subcutaneously into immunodeficient nu/nu mice. At 28 days after transplantation, areas with bone-like morphology were observed ( fig. 4 a) . Osteopontin immunohistochemistry showed that cells in these areas produce bone matrix ( fig. 4 b) . At 28 days after transplantation, Runx2 expression, measured by Q RT-PCR, was 2.4-fold higher in Sca-1 -implants than in Sca-1 + implants in 3 out of 4 experiments ( fig. 4 c) . Osteocalcin expression was 11.5-fold higher in Sca-1 -implants than in Sca-1 + implants in 3 out of 4 experiments ( fig. 4 d) . Furthermore, the percentage of bone area per implant, determined by computer-assisted histomorphometry, showed that Sca-1 -implants had 23.7% (n = 3) bone area while Sca-1 + implants had only 6.9% (n = 3) bone area ( fig. 4 e) . Expression of collagen type II, characteristic of cartilage, was 60.1-fold higher in Sca-1 -implants compared to Sca-1 + implants in 3 out of 4 experiments ( fig. 4 f) and this was almost significant (p = 0.0578). These results suggest that transplanted Sca-1 -cells differentiate into bone and cartilage after in vivo transplantations. Sca-1 + cells were also seeded in Gelfoam sponges and implanted in nu/nu mice subcutaneously, but no adipogenic differentiation was found after 4 weeks in the animal.
Discussion
Consistent with our recent studies on cells from fetal mouse calvaria [Steenhuis et al., 2008] , we show here that the Sca-1 + cell fraction from postnatal mouse calvaria has adipogenic differentiation potential, and that the Sca-1 -cell fraction has osteogenic differentiation potential in vitro and osteochondrogenic differentiation potential in vivo. In contrast to fetal cells, postnatal calvarial cells retain some of their differentiation potential after in vitro expansion, which would be important for possible therapeutic use of calvaria-derived progenitor cells. A further difference between fetal and postnatal calvarial cells, is that von Kossa staining could not detect mineralization in postnatal cells (not shown). Additionally, we detected cartilage markers in fetal Sca-1 -cells upon so-called micromass culture in vitro [Steenhuis et al., 2008] , but no cartilage nodules formed in micromass culture when using cells from 21-day-old animals (not shown). This suggests that the cells from older animals may have partially lost their chondrogenic and osteogenic differentiation potential. However, it could also indicate that culture methods for the postnatal cell were not optimal. Like BM-MSC [Pettway et al., 2005] , calvarial Sca-1 -cells differentiate into bone when transplanted subcutaneously. In addition, we detected chondrogenic differentiation ( fig. 4 f) , which was not evaluated in the BM-MSC study [Pettway et al., 2005] .
There are significant differences between alkaline phosphatase expression and Runx2 expression in primary and passage 4 Sca-1 -cell populations ( fig. 3 ). Whereas alkaline phosphatase upregulation upon osteogenic induction is greatly diminished at passage 4, Runx2 upregulation is only partially reduced at passage 4 compared to primary Sca-1 cells. However, Runx2 is an earlier osteogenic marker than alkaline phosphatase. Therefore it is possible that the Sca-1 -cells start osteogenic differentiation but that osteogenesis is inhibited in passage 4 cells at a stage before the cells start expressing alkaline phosphatase.
In vitro osteogenic and adipogenic induction, followed by staining and Q RT-PCR, was performed on cells in in- Fig. 4 . Sca-1 -calvarial cells differentiate into bone in vivo following subcutaneous transplantation. a HE staining shows that Sca-1 -implants have a bone-like morphology at 28 days after transplantation. b Osteopontin immunohistochemistry verifies that Sca-1 -cells produce bone matrix (arrows indicate positive staining, red). Expression of Runx2 ( c ) and osteocalcin ( d ) is increased in Sca-1 -implants at 28 days after transplantation. * p = 0.0002; * * p = 0.0009. e Sca-1 -implants produce more bone than Sca-1 + implants. * * * p ! 0.0001. f Expression of collagen type II, suggestive of cartilage formation, was higher in Sca-1 -implants than Sca-1 + implants. * * * * p = 0.0578. Panels a and b show a representative example of 3 independent experiments from 3 independent cell isolates. Scale bar = 100 m. Panels c-f represent the mean values of 3 independent experiments from 3 independent cell isolates.
duction medium and on cells in expansion medium. Our results show that neither the Sca-1 + cell fraction nor the Sca-1 -cell fraction displayed differentiation characteristics when cultured in expansion medium ( fig. 2 c, f, 3 c, f; staining not shown), indicating that the isolated calvarial cells are undifferentiated mesenchymal progenitor cells and not mature osteoblasts or mature adipocytes. Successful tissue regeneration and repair depends upon the ability to expand stem/progenitor cells. Because there are limitations on the number of cells that can be harvested from a donor site, stem/progenitor cells need to be culture-expanded to obtain sufficient numbers for clinical use. BM-MSC, which are well-characterized mesenchymal stem/progenitor cells, retain their in vitro differentiation capacity after culture expansion [Goshima et al., 1991; Bruder et al., 1997; Krebsbach et al., 1997 Krebsbach et al., , 1999 . We show here that calvarial cells isolated from 21-day-old mice retain some differentiation potential following culture expansion, suggesting that these cells may also be useful for tissue regeneration and repair.
Several studies demonstrate the feasibility of tissue regeneration and repair using tissue engineering or cell replacement therapy by BM-MSC. BM-MSC have been used in animal models for tissue engineering of mesenchymal tissues such as bone, cartilage, tendon, marrow stroma and muscle [Caplan and Bruder, 2001; Caplan, 2005] . Horwitz et al. [1999 Horwitz et al. [ , 2001 Horwitz et al. [ , 2002 applied cell replacement therapy by intravenous infusions of unmanipulated, allogeneic bone marrow in 3 children with osteogenesis imperfecta. Three months after treatment, histological analysis of the trabecular bone showed new dense bone formation and all patients had increases in total body bone mineral content that were associated with reduced frequencies of bone fracture. Similar to BM-MSC, calvaria-derived Sca-1 -osteoprogenitors may be used for tissue engineering or cell replacement therapy to treat craniofacial disorders.
Sca-1 antibodies have previously been used in combination with other markers to isolate hematopoietic stem cells [Spangrude et al., 1988; Aguila and Weissman, 1996; Bachar-Lustig et al., 1999; Gussoni et al., 1999; Lagasse et al., 2000; Bailey et al., 2004] , skeletal muscle stem cells [Gussoni et al., 1999] and mammary epithelial stem cells [Welm et al., 2002] . Furthermore, mesenchymal progenitor cells from rat and mouse bone marrow, fat pads, rib periosteum and skin also express Sca-1 [Van Vlasselaer et al., 1994; Baddoo et al., 2003; Gojo et al., 2003; Lee et al., 2003; Peister et al., 2004; Wolnicka-Glubisz et al., 2005; Park et al., 2006] , suggesting that Sca-1 is a common mesenchymal stem/progenitor cell marker. The common mesenchymal stem cell markers Stro-1, ALCAM and Endoglin [reviewed in Barry and Murphy, 2004] are not expressed in mouse calvaria in vivo or in calvaria-derived cells in vitro (unpublished results). However, we suspect that other cell surface markers will precisely define the properties and differentiation potential of calvarial cell populations. For example, such markers may be found in the SDF-1/CXCR4 and HGF/c-met signal transduction axes that are involved in BM-MSC migration [Son et al., 2006] . Furthermore, the colony-forming efficiencies of Stro-1 + , HOP-26 + , CD49a + and ALCAM + /SB-10 + /CD166 + BM-MSC are different [Stewart et al., 2003 ]. These markers could also be studied in calvarial cell populations. Additional markers for specific osteogenic stages, such as the early osteogenic marker alkaline phosphatase, may also be used to purify populations of stem/progenitor cells [Purpura et al., 2003] . Enhanced tissue regeneration and repair using mesenchymal stem/progenitor cells will likely depend on our ability to isolate relatively pure fractions of cells that possess the ideal properties for a given clinical situation. Detailed knowledge about the immunological profile and properties of such cells will be essential.
